Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.

Autor: Sharma R; Global Health Medicines R&D, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK., Sharma H; GSK, Brentford, Middlesex, UK., Jones S; GSK, Brentford, Middlesex, UK., Borghini-Fuhrer I; Medicines for Malaria Venture, Geneva, Switzerland., Domingo GJ; PATH, Seattle, WA, USA., Gibson RA; Global Health Medicines R&D, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK. rachel.a.gibson@gsk.com., Rolfe K; Global Health Medicines R&D, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK., Tan L; GSK, Brentford, Middlesex, UK., Fiţa IG; GSK, Brentford, Middlesex, UK., Chen C; GSK, Brentford, Middlesex, UK., Bird P; GSK, Brentford, Middlesex, UK., Pingle A; GSK, Mumbai, India., Duparc S; Medicines for Malaria Venture, Geneva, Switzerland.

Publikováno v: Malaria journal [Malar J] 2024 May 13; Vol. 23 (1), pp. 145. Date of Electronic Publication: 2024 May 13.

Tafenoquine for the radical cure versus prophylaxis of Plasmodium vivax malaria: the importance of using the appropriate data set.

Autor: Sharma R; Clinical Pharmacology Modelling and Simulation, Middlesex, UK., Chen C; Clinical Pharmacology Modelling and Simulation, Middlesex, UK., Fiţa IG; Safety Evaluation and Risk Management, Middlesex, UK., Gibson RA; Global Health Medicines R&D, Middlesex, UK., Jones S; Clinical Safety and Pharmacovigilance, Middlesex, UK., Pingle A; Global Health Access, GSK, Mumbai, Maharashtra, India., Rolfe K; Biostatistics, GSK, Stevenage, Hertfordshire, Middlesex, UK., Sharma H; Global Health, GSK, Brentford, Middlesex, UK., Bird P; Global Health, GSK, Brentford, Middlesex, UK.

Publikováno v: The Indian journal of medical research [Indian J Med Res] 2023 Aug; Vol. 158 (2), pp. 204-210.